January 27, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Iluvien receives marketing authorization in Finland, Luxembourg
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg have granted Iluvien marketing authorization for the treatment of vision impairment associated with chronic diabetic macular edema, according to a press release from Alimera Sciences.
Iluvien (fluocinolone acetonide intravitreal implant) is approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States. It is commercially available in the United Kingdom, Germany and Portugal, the release said.
Alimera plans to commercialize Iluvien in the U.S. starting in February, the release said.